EPL Limited has approved the merger with Indovida India Private Limited, establishing one of the largest consumer packaging platforms focused on emerging markets, projected to achieve ~$1 billion in revenue. The transaction values EPL at INR 339 per share, offering a ~35% multiple discount for Indovida. The merger is expected to be EPS accretive from the first full year of operations, combining EPL’s flexible packaging expertise with Indovida’s rigid PET capabilities.
Strategic Rationale: Creating a Packaging Leader for Emerging Markets
EPL Limited announced the approval of the merger with Indovida India Private Limited on March 29, 2026. This strategic move aims to create a leading consumer packaging platform focusing on emerging markets, anticipating a combined revenue of ~$1 billion. The rationale is built on five key pillars:
- Scale: The merged entity is positioned as one of the leading platforms for emerging markets.
- Growth Potential: Focus on emerging markets (estimated at ~75% of MergeCo revenue as of CY25), supported by comprehensive product portfolios and expansion headroom.
- Multiple Accretive: EPL is valued at INR 339 per share (~70% higher than the last closing price), while Indovida is valued at a ~35% discount to the multiple ascribed to EPL.
- Margin Accretive: The merger is expected to be EBIT margin accretive (120+bps) and ROCE accretive (220+bps) for EPL.
- Synergies: Identified synergies between $35-50 million across geography, product capabilities, and costs are expected to drive EBITDA upside.
Combination Overview: Enhanced Scale and Financial Profile (CY25 Estimates)
The combination results in a diversified, multi-format player with significant scale, supported by complementary strengths:
| Metric | EPL | Indovida | Merged Entity |
|---|---|---|---|
| Revenue (INR bn) | 45.7 | 38.1 | 83.8 |
| EBITDA (INR bn) / Margin | 9.3 / 20.4% | 8.1 / 21.3% | 17.5 / 20.9% |
| Net Debt / EBITDA | 0.65x | (0.20)x | 0.25x |
| Manufacturing Footprint | 21 sites / 11 countries | 19 sites / 9 countries | 40 sites / 17 countries |
The merged entity’s geographic mix is heavily weighted towards emerging markets, with ~75% of revenue expected from these regions, which are growing at ~2x developed economies.
Product Synergy and Market Position
The merger unites EPL’s flexible specialty packaging (laminates, tubes, caps & closures) with Indovida’s rigid PET packaging (preforms, bottles, closures), creating an end-to-end solution provider. Both companies hold leading market positions in their respective segments across key geographies:
- EPL Market Position (Laminated Tubes): Holds the number one position across AMESA, EAP, Europe, and Americas.
- Indovida Market Position (Rigid PET): Holds strong positions in countries like N. Ireland, Philippines, Vietnam, Nigeria, and Egypt.
The combined scale enables opportunities for growth in adjacent product categories such as Specialty Caps and Closures and Rigid Custom Containers for B&C, both representing global market sizes of INR 80-90K Crore.
Financial Enhancements and Synergies
The combined entity is expected to see significant financial improvements:
- Revenue doubles to INR 83.8 billion (CY25).
- EBITDA Margin is accretive, moving from 20.4% (EPL) to 20.9% (MergeCo).
- ROCE improves to 20.9% (up from 18.7% for EPL).
- Net Debt/EBITDA ratio is significantly improved to a conservative 0.25x.
Identified cost synergies of $35-50 million will be realized through procurement leverage, network optimization, organizational streamlining, and IT consolidation.
Indorama Ventures’ Role and Governance
Indorama Ventures (IVL) will become a Promoter post-merger, holding a 51.8% stake in MergeCo. This parentage is expected to provide access to global operating expertise, capital support, and reinforced alignment with global customers. The leadership structure includes Mr. Hemant Bakshi as MD and Global CEO of the MergeCo.
Transaction Timeline
The transaction closure is estimated to occur within approximately ~12 months, pending completion of necessary regulatory approvals, including filings with SEBI, CCI, and NCLT procedures, spanning from Q4FY26 through Q4FY27.
Source: BSE
